Company news
Neurotech International Ltd. (ASX:NTI) news
Neurotech International Ltd. news releases on 6ix. Latest, Jul 10, 2023: NTI Receives HREC Approval for Rett Syndrome Clinical Trial
Press releases — page 2
NTI Receives HREC Approval for Rett Syndrome Clinical Trial
July 9, 2023
NTI Granted 2 Year Extension of Treatment for ASD Patients
May 30, 2023
NTI granted HREC Approval for PANDAS/PANS Trial Extension
May 29, 2023
NTI Completes Recruitment in PANDAS/PANS Clinical Trial
May 2, 2023
NTI to Launch Phase II Clinical Trial in Rett Syndrome
March 19, 2023
Phase I/II ASD Clinical Trials Results at 52 Weeks
March 16, 2023
First Patient Treated in Phase I/II PANDAS/PANS Trial
February 16, 2023
Approval for Additional Phase I/II ASD Trial Extension
February 13, 2023
HREC Approval for Phase I/II PANDAS/PANS Clinical Trial
January 26, 2023
NTI Granted FDA Pre-IND Meeting for NTI164 in ASD
January 19, 2023
Disclosure Document
December 22, 2022
Commencement of Phase II/III ASD Clinical Trial
December 19, 2022
NTI Receives HREC/TGA Approval for Phase II/III ASD Trial
November 16, 2022
Neurotech Receives $1.2M R&D Tax Rebate
October 31, 2022
Reinstatement to Quotation
October 27, 2022
Neurotech Completes $9.0M Placement
October 27, 2022
Suspension From Official Quotation
October 26, 2022
20 Week Data Shows Significant Improvement For ASD Children
October 25, 2022
New Phase I/II Clinical Trial in Children with PANDAS/PANS
October 16, 2022
Executive Change
September 1, 2022
Q&A on NTI164 Breakthrough Clinical Trial Results in ASD
July 21, 2022
Reinstatement to Official Quotation
July 7, 2022
BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD
July 7, 2022
Extension to Voluntary Suspension
July 7, 2022
Suspension from Official Quotation
July 6, 2022
Preclinical Success with Targeted Combination Therapies
June 9, 2022
Successful Landmark Study in Paediatric ASD
April 4, 2022
Neurotech International : Notification regarding unquoted securities - NTI
March 10, 2022
Neurotech International : Proposed issue of securities - NTI
March 3, 2022
Appointment of Chief Executive Officer
March 2, 2022
Neurotech International : Application for quotation of securities - NTI
January 24, 2022
Response to ASX Query Letter
October 13, 2021
Appendix 4E and Annual Report
August 29, 2021
Quarterly Report and Appendix 4C
July 29, 2021
Neurotech Expands License with Dolce Cann Global
March 1, 2021
Successful Completion of In Vitro Studies
December 20, 2020
Further Success with Preliminary In-vitro Studies
November 29, 2020
Voluntary Suspension
November 26, 2020
Interim Results and Capital Raising
November 1, 2020
Response to ASX Price and Volume Query
October 22, 2020
Neurotech Proceeds to in vitro trials after Positive Results
September 6, 2020
Response to ASX price query
August 21, 2020
Pause in Trading
August 20, 2020
NTI Secures Option to Cannabis Strains Targeting Autism
July 3, 2020
Mente receives CE Mark renewal for use with ASD Children
April 8, 2020
Response to Appendix 4C Query
February 17, 2020
Cancellation of Mente Device from Australian TGA Register
January 27, 2020
Appendix 4E and Annual Report to Shareholders
August 30, 2019
Quarterly Update & Appendix 4C
July 31, 2019
Pause In Trading
May 29, 2019